Antithrombotic activity of a new P2[Y.sub.1] receptor antagonist, substance Sbt-119, on experimental models of thromboses in rats

Antithrombotic properties of a new P2[Y.sub.1] receptor antagonist N-[(1-morpholinopropyl-amino)carbonyl-2-(1-ethyl-1H- indole-3-yl)-vinyl]-4-methylphenyl-amide hydrochloride, substance Sbt-119, and reference drug ticlopidine were studied on experimental models of arterial and systemic thromboses. S...

Full description

Saved in:
Bibliographic Details
Published inBulletin of experimental biology and medicine Vol. 158; no. 1; p. 53
Main Authors Yakovlev, D.S, Spasov, A.A, Bukatina, T.M, Smirnov, A.V, Suzdalev, K.F
Format Journal Article
LanguageEnglish
Published Springer 01.11.2014
Subjects
Blood clot
Thrombosis
Online AccessGet full text

Cover

More Information
Summary:Antithrombotic properties of a new P2[Y.sub.1] receptor antagonist N-[(1-morpholinopropyl-amino)carbonyl-2-(1-ethyl-1H- indole-3-yl)-vinyl]-4-methylphenyl-amide hydrochloride, substance Sbt-119, and reference drug ticlopidine were studied on experimental models of arterial and systemic thromboses. Substance Sbt-119 was 39.9% (p < 0.05) more potent than ticlopidine in producing the antithrombotic effect. Moreover, substance Sbt-119 was shown to increase the survival rate of animals after systemic treatment with ADP (by 20%, p < 0.0001). This substance decreased the number of mural thrombi and reduced the severity of hemodynamics disturbances in the organs during systemic thrombosis. Key Words: indole derivatives; P2[Y.sub.1] receptor antagonists; arterial thrombosis; ADP-induced systemic thrombosis; ticlopidine
ISSN:0007-4888
1573-8221
DOI:10.1007/s10517-014-2690-y